{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:42Z","timestamp":1761895902779},"reference-count":41,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3960\/jslrt.54.31","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T23:13:54Z","timestamp":1403046834000},"page":"31-37","source":"Crossref","is-referenced-by-count":18,"title":["Treatment of Follicular Lymphoma"],"prefix":"10.3960","volume":"54","author":[{"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Sebban C, Mounier N, Brousse N, Belanger C, Brice P<I>,<\/I> <I>et al<\/I>.: Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108:2540-2544, 2006"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, <I>et al<\/I>.: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"3","unstructured":"3 Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, <I>et al<\/I>.: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006"},{"key":"4","unstructured":"4 Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, <I>et al<\/I>.: Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 122:981-987, 2013"},{"key":"5","unstructured":"5 Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, <I>et al<\/I>.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, <I>et al<\/I>.: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"7","unstructured":"7 Herold M, Haas A, Srock S, Neser S, Al-Ali KH, <I>et al<\/I>.: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007"},{"key":"8","unstructured":"8 Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, <I>et al<\/I>.: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL 2000 study. Blood 112:4824-4831, 2008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, <I>et al<\/I>.: Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 98:1107-1114, 2013","DOI":"10.3324\/haematol.2012.082412"},{"key":"10","unstructured":"10 Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, <I>et al<\/I>.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706-714, 2007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Marcus R, Imrie K, Belch A, Cunningham D, Flores E, <I>et al<\/I>.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005","DOI":"10.1182\/blood-2004-08-3175"},{"key":"12","unstructured":"12 Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, <I>et al<\/I>.: R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL 05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506-1513, 2013"},{"key":"13","unstructured":"13 Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, <I>et al<\/I>.: Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol 29:3990-3998, 2011"},{"key":"14","unstructured":"14 Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr&uuml;nhagen U, <I>et al<\/I>.: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Flinn IW, Van der Jagt RH, Kahl BS, Wood P: An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The BRIGHT Study. Blood (ASH Annual Meeting Abstracts): abstract 902, 2012","DOI":"10.1182\/blood.V120.21.902.902"},{"key":"16","unstructured":"16 Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, <I>et al<\/I>.: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667-2674, 2004"},{"key":"17","unstructured":"17 Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, <I>et al<\/I>.: High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105:3817-3823, 2005"},{"key":"18","unstructured":"18 Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, <I>et al<\/I>.: Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004-4013, 2008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, <I>et al<\/I>.: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"20","unstructured":"20 Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, <I>et al<\/I>.: <SUP>90<\/SUP>Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol 31:1977-1983, 2013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, <I>et al<\/I>.: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215-2223, 2005","DOI":"10.1200\/JCO.2005.06.146"},{"key":"22","unstructured":"22 Salles G, Seymour JF, Offner F, L&oacute;pez-Guillermo A, Belada D, <I>et al<\/I>.: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51, 2011"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984","DOI":"10.1056\/NEJM198412063112303"},{"key":"24","unstructured":"24 Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, <I>et al<\/I>.: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516-522, 2003"},{"key":"25","unstructured":"25 Solal-C&eacute;ligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, <I>et al<\/I>.: Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 30:3848-3853, 2012"},{"key":"26","unstructured":"26 Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, <I>et al<\/I>.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101-106, 2001"},{"key":"27","unstructured":"27 Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, <I>et al<\/I>.: Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol 23:2380-2385, 2012"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Ardeshna KM, Smith P, Qian W, Warden J: An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood (ASH Annual Meeting Abstracts): abstract 6, 2010","DOI":"10.1182\/blood.V116.21.6.6"},{"key":"29","unstructured":"29 Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, <I>et al<\/I>.: Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 30:3368-3375, 2012"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, <I>et al<\/I>.: Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-2122, 2003","DOI":"10.1200\/JCO.2003.07.111"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, <I>et al<\/I>.: Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci 100:1951-1956, 2009","DOI":"10.1111\/j.1349-7006.2009.01247.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, <I>et al<\/I>.: Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101:2059-2064, 2010","DOI":"10.1111\/j.1349-7006.2010.01635.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, <I>et al<\/I>.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005","DOI":"10.1200\/JCO.2005.08.100"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, <I>et al<\/I>.: Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 37:157-161, 2000","DOI":"10.3109\/10428190009057639"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, <I>et al<\/I>.: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 26:5165-5169, 2008","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Bastion Y, Sebban C, Berger F, Felman P, Salles G, <I>et al<\/I>.: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997","DOI":"10.1200\/JCO.1997.15.4.1587"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, <I>et al<\/I>.: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426-2433, 2007","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, <I>et al<\/I>.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002","DOI":"10.1200\/JCO.2002.11.017"},{"key":"39","unstructured":"39 Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, <I>et al<\/I>.: Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26:204-210, 2008"},{"key":"40","unstructured":"40 Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, <I>et al<\/I>.: Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol 31:1164-1171, 2013"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Bodet-Milin C, Kraeber-Bod&eacute;r&eacute; F, Moreau P, Campion L, Dupas B, <I>et al<\/I>.: Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 93:471-472, 2008","DOI":"10.3324\/haematol.12013"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:53Z","timestamp":1621540013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/54\/1\/54_31\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.54.31","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}